BioWorld

Oct. 25, 2002

View Archived Issues

Chiron Reports Strong Earnings, Cuts Three Late-Stage Programs

Chiron Corp. reported robust third-quarter earnings, topping the Street's estimate by 14 cents per share, but also said it was dropping three late-stage programs, leaving some questioning the depth of its pipeline. (BioWorld Today) Read More

OSI Drops Diabetes Program, Puts Full Focus On Oncology

Read More

Estren, Novel Hormone Substitute, Obviates Menopausal Bone, Breast Cancer Adversities - So Far In Mice

Read More

Amylin Pulls Symlin Filing In Europe; Problem Not Identified

Read More

Other News To Note

Read More

Vertex Expects Regulatory Filing For HIV Drug On Phase III Data

Read More

Appointments And Advancements

Read More